ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Renal Allografts Demonstrate Improved Pathology After Belatacept Therapy

T. Saavedra,1 O. Opara,1 R. McLoughlin,1 B. Philosophe,2 C. Drachenberg,1 M. Weir,1 S. Bartlett,1 D. Leeser,1 J. Bromberg,1 R. Barth.1

1University of Maryland School of Medicine, Baltimore
2Johns Hopkins University, Baltimore.

Meeting: 2015 American Transplant Congress

Abstract number: B69

Keywords: Co-stimulation, Kidney transplantation, Rejection, Renal function

Session Information

Session Name: Poster Session B: Clinical Science: Kidney Immunosuppression: Novel Agents

Session Type: Poster Session

Date: Sunday, May 3, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Belatacept provides immunosuppression via costimulation blockade and has been associated with improved renal function compared to calcineurin inhibitor based therapies. We developed the Maryland Aggregate Pathology Index (MAPI) to identify kidneys with pre-existing pathology (MAPI ≥ 8) that predicted grafts with poorer outcomes. We investigated the use of belatacept with these kidneys to determine outcomes.

Methods:

Investigator initiated trial was developed to prospectively study patients with MAPI ≥ 8 to receive belatacept immunosuppression for 12 months. Patients received alemtuzumab induction therapy (30 mg), mycophenolate mofetil (MMF), and steroid withdrawal over 21 days. Biopsies were performed pre-transplant, and at 3 and 12 months, and renal function and infectious complications were monitored.

Results:

17 eligible patients underwent renal transplantation with MAPI ≥ 8 kidneys. Four patients discontinued the study secondary to surgical complication aborting transplant, primary non-function, non-compliance, and rejection. Patients were average 55.1 y/o, 76 % African-American, and 68% male. Delayed graft function was observed in 67% patients. No cases of post-transplant lymphoproliferative disorder (PTLD) or progressive multifocal leukoencephalopathy (PML)were observed. Average pre-implant MAPI score was 9, which was observed to decrease to a score of 3 at 3 months (p<0.01), and a score of 4 at 12 months (p<0.01) post-transplant. All patients were weaned off steroids. Rejection was observed in 3 patients on therapy (19%), one of whom had multiple episodes and was converted to tacrolimus. Average creatinine level was 1.75 mg/dL at 3 months and 1.89 mg/dL at 12 months. Average glomerular filtration rate was 62 mL/min at 3 months and 54 mL/min at 12 months. Most common adverse events were gastrointestinal intolerability and urinary tract infection.

Conclusion:

Belatacept/MMF therapy combined with alemtuzumab induction and steroid withdrawal provided good outcomes in kidneys with significant pre-transplant pathology. Despite high delayed graft function rates, rejection rates were low and kidney function was good at 3 and 12 months. MAPI pathology scores significantly improved post-transplant with belatacept therapy suggesting reversibility of pre-transplant pathologic findings.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Saavedra T, Opara O, McLoughlin R, Philosophe B, Drachenberg C, Weir M, Bartlett S, Leeser D, Bromberg J, Barth R. Renal Allografts Demonstrate Improved Pathology After Belatacept Therapy [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/renal-allografts-demonstrate-improved-pathology-after-belatacept-therapy/. Accessed May 9, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences